Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2008 2
2009 1
2010 2
2011 3
2012 3
2013 6
2014 3
2015 2
2016 10
2017 6
2018 10
2019 8
2020 9
2021 10
2022 8
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Restoring tumor immunogenicity with dendritic cell reprogramming.
Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, Met Ö, Caiado I, Shapiro IE, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério-Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa FF, Pires CF, Bassani-Sternberg M, Svane IM, Pereira CF. Zimmermannova O, et al. Among authors: met o. Sci Immunol. 2023 Jul 14;8(85):eadd4817. doi: 10.1126/sciimmunol.add4817. Epub 2023 Jul 7. Sci Immunol. 2023. PMID: 37418548 Free PMC article.
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Rohaan MW, et al. Among authors: met o. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. N Engl J Med. 2022. PMID: 36477031 Clinical Trial.
Principles of adoptive T cell therapy in cancer.
Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Met Ö, et al. Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5. Semin Immunopathol. 2019. PMID: 30187086 Review.
[Chimeric antigen receptor T-cell therapy].
Müller K, Ifversen M, Kielsen K, Petersen SL, Met Ö, Svane IM. Müller K, et al. Among authors: met o. Ugeskr Laeger. 2019 Oct 14;181(20A):V05190309. Ugeskr Laeger. 2019. PMID: 31610841 Free article. Review. Danish.
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.
Mortensen REJ, Holmström MO, Lisle TL, Hasselby JP, Willemoe GL, Met Ö, Marie Svane I, Johansen J, Nielsen DL, Chen IM, Andersen MH. Mortensen REJ, et al. Among authors: met o. J Immunother Cancer. 2023 Mar;11(3):e006432. doi: 10.1136/jitc-2022-006432. J Immunother Cancer. 2023. PMID: 36948507 Free PMC article. Clinical Trial.
SATB1 in Malignant T Cells.
Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL, Friese C, Blümel E, Petersen DL, Hu T, Nastasi C, Lindahl LM, Buus TB, Krejsgaard T, Wasik MA, Kopp KL, Koralov SB, Persson JL, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Becker JC, Ødum N. Fredholm S, et al. Among authors: met o. J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8. J Invest Dermatol. 2018. PMID: 29751003 Free article.
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm SA, Frej MS, Rafa VM, Hansen UK, Ormhøj M, Tyron A, Jensen AWP, Kadivar M, Bentzen AK, Munk KK, Aasbjerg GN, Ternander JSH, Heeke C, Tamhane T, Schmess C, Funt SA, Kjeldsen JW, Kverneland AH, Met Ö, Draghi A, Jakobsen SN, Donia M, Marie Svane I, Hadrup SR. Tvingsholm SA, et al. Among authors: met o. J Immunother Cancer. 2023 Aug;11(8):e006847. doi: 10.1136/jitc-2023-006847. J Immunother Cancer. 2023. PMID: 37586765 Free PMC article.
83 results